^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ROS1 positive

    i
    Other names: ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
    Entrez ID:
    6098
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    NRF2-Driven CARM1 Promotes Malignant Progression and Ferroptosis Resistance in Breast Cancer. (PubMed, Curr Cancer Drug Targets)
    NRF2 directly binds to and transcriptionally activates CARM1, thereby enhancing ferroptosis resistance and promoting TNBC progression. These findings reveal a novel molecular mechanism underlying TNBC malignancy and suggest that targeting the NRF2-CARM1 axis, particularly in combination with ferroptosis inducers, may provide a potential strategy for TNBC treatment.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    ROS1 positive • NFE2L2 mutation
    3d
    Corynoxine suppresses hepatocellular carcinoma progression by forming the ROS-STAT3 cycle. (PubMed, Toxicol Appl Pharmacol)
    Consistent with our in vitro observations, in vivo xenograft experiments verified that Cory retarded HCC tumor growth by modulating ROS and STAT3 activity. In summary, this study demonstrates Cory impedes HCC progression via a ROS-STAT3 positive feedback loop, suggesting that Cory may serve as a promising therapeutic candidate for HCC treatment.
    Journal
    |
    IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    ROS1 positive
    4d
    Prognostic value of ROS1 rearrangement in lung adenocarcinoma stratified by clinicopathologic and radiological features: a retrospective cohort study. (PubMed, Transl Lung Cancer Res)
    The rate of bone metastasis was significantly higher in ROS1 rearrangement-positive than in ROS1 rearrangement-negative patients. ROS1 rearrangement plays a significant prognostic role in advanced progression of LUAD; however, the generally favorable survival outcomes of early-stage LUAD may obscure its prognostic value.
    Retrospective data • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 positive • ROS1 rearrangement
    11d
    Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
    New trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ROS1 positive
    |
    Lorbrena (lorlatinib)
    19d
    The LncRNA MIAT acts as a sponge for miR-942-5p to exacerbate the inflammation and oxidative stress in macrophages during sepsis-associated liver injury. (PubMed, BMC Immunol)
    The silence of MIAT alleviated the inflammatory response and oxidative stress in LPS-induced RAW264.7 and alleviated the damage of AML-12 cells by adsorbing miR-942-5p.
    Journal
    |
    TXNIP (Thioredoxin Interacting Protein) • MIAT (Myocardial Infarction Associated Transcript) • MIR942 (MicroRNA 942)
    |
    ROS1 positive
    25d
    Response to crizotinib treatment for ROS1 p.H1999N mutation and secondary EGFR p.V774M mutation after drug resistance: a Case Report. (PubMed, Front Pharmacol)
    Subsequently, the patient received furmonertinib targeted therapy. Herein, we discuss the diagnostic challenges and the potential pathogenic mechanisms of this novel mutation. How to identify rare genes and translate their identification into clinical benefits is a worthwhile avenue for exploration in our future work.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ROS1 fusion • ROS1 positive
    |
    Xalkori (crizotinib) • Ivesa (firmonertinib)
    28d
    Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib. (PubMed, Transl Lung Cancer Res)
    No statistically significant difference was observed (P=0.65). This study did not find evidence that baseline PD-L1 expression significantly influences the efficacy of entrectinib in advanced ROS1-rearranged NSCLC patients.
    Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • PD-L1 negative • ROS1 positive • ROS1 rearrangement
    |
    Rozlytrek (entrectinib)
    30d
    Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Bristol-Myers Squibb
    New trial
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • ROS1 positive
    |
    Augtyro (repotrectinib)
    1m
    A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, CStone Pharmaceuticals | Trial completion date: May 2026 --> May 2027
    Trial completion date
    |
    ROS1 positive
    |
    Xalkori (crizotinib) • Lorbrena (lorlatinib)
    1m
    IMP3-saRNA Vaccine in Advanced NSCLC (clinicaltrials.gov)
    P1, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • ALK positive • EGFR wild-type • ROS1 positive
    1m
    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. (PubMed, Oncologist)
    Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
    Journal • Adverse events
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • ROS1 positive • NTRK positive • NTRK fusion
    |
    Augtyro (repotrectinib)
    1m
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)